Perspectives on Managing Polycythemia Vera for the Nurse Practitioner and Physician Assistant
Program Objectives
Polycythemia Vera Overview
Patient Case 1 Initial Presentation
When to Suspect PV
Initial Workup for PV
WHO 2016 Diagnostic Criteria for PV
Patient Case 1 (cont)
Audience Question 1
Risk Stratification for Thrombosis in PV
Risk Factors for Decreased Survival in PV
Causes of Mortality in Patients With PV
PV Treatment Goals
Management of Disease Symptoms
Communication Between Providers and Patients/Caregivers
Communication Among the Healthcare Team
Cytoreductive Therapy
Symptomatic Profiles of Patients With PV According to HU Use
PV Risk-Adapted Treatment Strategy
Management of Treatment-Related AEs
Patient Case 1 2 Years Later
Evaluating Response to Treatment
Patient Case 1 Resolution
Patient Case 2 Presentation
Patient Case 2 (cont)
Resistance to or Intolerance of HU or IFNα
How to Determine Resistance to or Intolerance of HU
Audience Question 2
Alternative Therapies for PV Resistant to or Intolerant of HU
Pegylated IFNα2a for PV Phase 2 Study Responses
Pegylated IFNα2a for PV Molecular Response
Ruxolitinib
Mechanism of JAK-STAT Signaling
Ruxolitinib for PV Phase 3 RESPONSE Trial
RESPONSE Trial Efficacy Results
Ruxolitinib Dosing in PV
Ruxolitinib Dose Modifications
Ruxolitinib Safety Profile
Management of AEs
Patient Case 2 Treatment Plan
Summary and Conclusion
Abbreviations
Abbreviations